News
-
Moerae Matrix, which is developing inhaled therapies for the treatment of idiopathic pulmonary fibrosis and other lung diseases, has announced the appointment of Bill Bradford as Chief Medical Officer. Bradford was most recently a Senior… Read more . . .
-
The FDA has issued product-specific recommendations for demonstrating the bioequivalence of over 40 drug products, including several OINDPs. The newly added documents include guidances for azelastine HCL/fluticasone propionate nasal spray, budesonide/formoterol fumarate MDI, and levalbuterol… Read more . . .
-
Hovione is adding new spray drying capacity at its facility in Loures, Portugal, the company has announced. The company says that the new spray dryer, which is designed with the ability to handle highly potent… Read more . . .
-
According to the authors of an article published in The BMJ on July 1, 2015, the Global Initiative for Obstructive Lung Disease (GOLD) criteria for COPD diagnosis result in significant overdiagnosis and overprescription of inhalers,… Read more . . .
-
A study published online in CHEST on June 25, 2015 finds that discontinuing inhaled corticosteroids for COPD patients reduced the risk of pneumonia by 37%, with the greatest reduction in risk associated with stopping inhaled… Read more . . .
-
Teva Pharmaceutical’s DuoResp Spiromax multidose DPI has won a Silver award at the 2015 Medical Design Excellence Awards (MDEA), with Gerresheimer receiving credit as a supplier. DuoResp Spiromax received European marketing authorization in April 2014.… Read more . . .
-
According to Boehringer Ingelheim, the United Kingdom, Croatia, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain have approved the Spiolto Respimat tiotropium/olodaterol SMI for the treatment of COPD. BI recently announced the launch of the… Read more . . .
-
For podium presentations, submit 200-word summary by August 15, 2015 at http://www.rddonline.com/rdd/speaker_reg.php?id=12 For information on topics, see http://www.rddonline.com/rdd/rdd.php?id=12&sid=3 For posters, submit abstract by January 8, 2016. See http://www.rddonline.com/rdd/rdd.php?id=12&sid=4 for further information. Nominations for the Charles… Read more . . .
-
The Canadian Agency for Drugs and Technology in Health (CADTH) has issued a call for patient input regarding GSK’s Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of asthma. According to the announcement, the agency… Read more . . .
-
The Israeli Patent Office has issued Patent No. 193318, “System for Pulmonary Delivery of Alpha-1 Proteinase Inhibitor,” to Kamada and PARI Pharma, Kamada has announced. The patent relates to delivery of Kamada’s inhaled alpha-1 proteinase… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany